See more : Global Arena Holding Inc. (GAHC) Income Statement Analysis – Financial Results
Complete financial analysis of Phathom Pharmaceuticals, Inc. (PHAT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Phathom Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Septeni Holdings Co., Ltd. (4293.T) Income Statement Analysis – Financial Results
- Skandinaviska Enskilda Banken AB (publ) (SEBC.F) Income Statement Analysis – Financial Results
- Freshworks Inc. (FRSH) Income Statement Analysis – Financial Results
- Informatica Inc. (INFA) Income Statement Analysis – Financial Results
- Nine Dragons Paper (Holdings) Limited (2689.HK) Income Statement Analysis – Financial Results
Phathom Pharmaceuticals, Inc. (PHAT)
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 682.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 167.00K | 620.00K | 521.00K | 300.00K | 8.00K | 0.00 |
| Gross Profit | 515.00K | -620.00K | -521.00K | -300.00K | -8.00K | 0.00 |
| Gross Profit Ratio | 75.51% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 49.90M | 71.44M | 72.34M | 98.15M | 99.27M | 20.00K |
| General & Administrative | 0.00 | 101.00M | 62.74M | 27.52M | 6.94M | 1.21M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 117.93M | 101.00M | 62.74M | 27.52M | 6.94M | 1.21M |
| Other Expenses | 0.00 | -110.00K | -2.06M | -8.00K | -49.56M | -50.00K |
| Operating Expenses | 167.83M | 172.44M | 135.08M | 125.67M | 106.22M | 1.23M |
| Cost & Expenses | 167.99M | 172.44M | 135.08M | 125.67M | 106.22M | 1.23M |
| Interest Income | 7.88M | 2.13M | 41.00K | 1.09M | 1.09M | 0.00 |
| Interest Expense | 41.97M | 27.31M | 6.79M | 4.58M | 4.18M | 13.00K |
| Depreciation & Amortization | 575.00K | 620.00K | 521.00K | 300.00K | 8.00K | 1.23M |
| EBITDA | -159.05M | -171.82M | -134.56M | -124.19M | -250.95M | -50.00K |
| EBITDA Ratio | -23,320.97% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -167.31M | -172.44M | -135.08M | -125.67M | -106.22M | -1.23M |
| Operating Income Ratio | -24,532.55% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -34.28M | -25.28M | -8.80M | -3.40M | -148.92M | -63.00K |
| Income Before Tax | -201.59M | -197.72M | -143.88M | -129.07M | -255.13M | -1.29M |
| Income Before Tax Ratio | -29,558.94% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 25.28M | 4.21M | 4.25M | -45.39M | 13.00K |
| Net Income | -201.59M | -223.01M | -148.09M | -133.32M | -209.74M | -1.29M |
| Net Income Ratio | -29,558.94% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.93 | -5.70 | -4.00 | -4.01 | -8.48 | -0.15 |
| EPS Diluted | -3.93 | -5.70 | -4.00 | -4.01 | -8.48 | -0.15 |
| Weighted Avg Shares Out | 51.29M | 39.12M | 37.00M | 33.23M | 24.73M | 8.58M |
| Weighted Avg Shares Out (Dil) | 51.29M | 39.12M | 37.00M | 33.23M | 24.73M | 8.58M |
Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn
VOQUEZNA, the first and only FDA-approved potassium-competitive acid blocker (PCAB), is now available through major retail pharmacies and BlinkRx, an end-to-end digital fulfillment channel VOQUEZNA tablets in 30-count bottles are now commercially available for the healing and maintenance of healing of all...
Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates
FLORHAM PARK, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the third quarter of 2023 and provided updates...
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults
FLORHAM PARK, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today the U.S. Food and Drug Administration (FDA) has approved VOQUEZNA®...
Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
FLORHAM PARK, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced that the U.S. Food and Drug Administration (FDA) has approved the...
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
FLORHAM PARK, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team are scheduled to participate in...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)
NEW YORK , Oct. 23, 2023 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Phantom Pharmaceuticals, Inc. (NASDAQ: PHAT) concerning possible breaches of fiduciary duty. To obtain additional information, go to: https://zlk.com/compensation2/phathom-pharmaceuticals-inc-lawsuit-submission-form or contact Joseph E.
Following Up On Phathom Pharmaceuticals
Phathom Pharmaceuticals is a small biopharma firm focused on developing treatments for gastrointestinal diseases. The company has recently filed some marketing applications around its primary drug candidate. The company ended the second quarter with just under $250 million in cash...
Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD
FLORHAM PARK, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the submission of an NDA to the FDA for vonoprazan...
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
FLORHAM PARK, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team will participate in the following...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)
NEW YORK , Aug. 25, 2023 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Phantom Pharmaceuticals, Inc. (NASDAQ: PHAT) concerning possible breaches of fiduciary duty. To obtain additional information, go to: https://zlk.com/compensation2/phathom-pharmaceuticals-inc-lawsuit-submission-form or contact Joseph E.
Source: https://incomestatements.info
Category: Stock Reports